Regentron's scientific team has authored a Letter to the Editor in Surgical Innovation, a peer-reviewed SAGE journal focused on clinical and surgical technique innovation. The letter enters an active scholarly debate on the trajectory of clinical bioprinting — specifically, the strategic tension between ex vivo and in vivo approaches to organ and tissue fabrication.
In direct response, Vladimir Mironov and Alexey Kovalev have published a formal reply in the same journal. Mironov is one of the founding figures of organ bioprinting — co-author of the first scientific publication on organ printing in 2003 — and holds an H-index of 52 with over 200 peer-reviewed publications. Kovalev is Scientific Director at 3D Bioprinting Solutions. Their published response, "Clinical Bioprinting Is Coming of Age: Ex Vivo Versus In Vivo," engages directly with the arguments raised in Regentron's letter.
Regentron's scientific team is operating within the primary debate in clinical bioprinting. The arguments in the original letter were substantive enough to draw a named, formal published response from two of the field's most recognized practitioners.
Regentron's 12-paper publication program is underway. Future publications will include original research on the company's core platform technologies — in vivo bioreactor systems, biocomposite cell aggregates, and aerosol nutrient delivery — in indexed journals including Biofabrication, Tissue Engineering, and ACS Omega.